Ultragenyx Pharmaceutical Inc. (RARE) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Ultragenyx Pharmaceutical’s revenue went from $133000 in fiscal 2016 to $673M in fiscal 2025, growth of about 158.0% a year.
Net income in fiscal 2025 was -$575M, a net margin of -85.4%; the best year in this period was 2020 with -$187M.
Over the twelve months to September 30, 2026, revenue was $730M and net income -$524M.
Free cash flow was -$472M in fiscal 2025 and positive in 0 of the 10 years shown.
The diluted share count rose 149% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $730M | $673M | $560M | $434M | $363M | $351M | $271M | $104M | $51M | $3M | $133000 |
| Gross profit | — | — | — | — | — | — | — | — | $50M | $3M | — |
| Operating income | -$467M | -$535M | -$536M | -$569M | -$649M | -$382M | -$330M | -$424M | -$371M | -$329M | -$248M |
| Net income | -$524M | -$575M | -$569M | -$607M | -$707M | -$454M | -$187M | -$403M | -$198M | -$302M | -$246M |
| EPS (diluted) | $-5.18 | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 | $-3.07 | $-7.12 | $-3.97 | $-7.12 | $-6.21 |
| R&D | $711M | $750M | $698M | $648M | $706M | $497M | $412M | $357M | $294M | $232M | $183M |
| Revenue growth | — | +20.2% | +29.0% | +19.4% | +3.4% | +29.7% | +161.3% | +101.4% | +1871.5% | +1863.9% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$437M | -$466M | -$414M | -$475M | -$380M | -$339M | -$132M | -$345M | -$291M | -$254M | -$161M |
| Capital spending | -$5M | -$6M | -$7M | -$44M | -$116M | -$73M | -$44M | -$25M | -$4M | -$3M | -$10M |
| Free cash flow | -$442M | -$472M | -$421M | -$519M | -$497M | -$412M | -$176M | -$370M | -$295M | -$257M | -$171M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $105M | $153M | $158M | $135M | $130M | $105M | $86M | $82M | $80M | $68M | $48M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $680M | $610M | $578M | $748M | $740M | $1.2B | $755M | $460M | $234M | $380M |
| Debt | — | $36M | $40M | $43M | $31M | $41M | $47M | $37M | $0 | $0 | $0 |
| Equity | — | -$80M | $255M | $275M | $352M | $923M | $1.2B | $654M | $609M | $383M | $474M |
| Total assets | — | $1.5B | $1.5B | $1.5B | $1.5B | $1.5B | $1.8B | $1.1B | $720M | $491M | $541M |
| Shares (diluted) | 102M | 99M | 90M | 74M | 70M | 68M | 61M | 57M | 50M | 42M | 40M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | 97.8% | 100.0% | — |
| Operating margin | -64.0% | -79.5% | -95.7% | -131.1% | -178.6% | -108.6% | -121.8% | -409.0% | -721.2% | -12593.5% | -186500.0% |
| Net margin | -71.8% | -85.4% | -101.6% | -139.9% | -194.7% | -129.2% | -68.8% | -388.3% | -383.8% | -11567.3% | -184900.0% |
| FCF margin | -60.5% | -70.1% | -75.2% | -119.6% | -136.7% | -117.2% | -65.0% | -357.0% | -572.2% | -9825.3% | -128700.0% |
| ROIC | — | — | -143.4% | -178.2% | -133.7% | -31.3% | -21.7% | -48.5% | -48.2% | -81.4% | -41.3% |
| ROE | — | 718.8% | -223.1% | -220.7% | -201.0% | -49.2% | -16.2% | -61.6% | -32.5% | -78.8% | -51.9% |
Frequently asked questions
What is Ultragenyx Pharmaceutical’s annual revenue?
$673M in fiscal 2025 and $730M over the twelve months to September 30, 2026.
How much profit does Ultragenyx Pharmaceutical make?
Net income was -$575M in fiscal 2025 (net margin -85.4%).
Is Ultragenyx Pharmaceutical’s revenue growing?
Yes: revenue rose 20.2% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.